Guizhou Yibai Pharmaceutical Valuation

Q: What is the Fair Price of 600594 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

600594 (CN¥3.82) is trading above our estimate of [[fair value]] (CN¥0.07)

Is 600594 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600594 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600594 (CN¥3.82) is trading above our estimate of fair value (CN¥0.07)

Significantly Below Fair Value: 600594 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600594?

Key metric: As 600594 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 600594. This is calculated by dividing 600594's market cap by their current revenue.
What is 600594's PS Ratio?
PS Ratio	1.3x
Sales	CN¥2.40b
Market Cap	CN¥3.01b

600594 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	83.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 600594's PS Ratio compare to its peers?

The above table shows the PS ratio for 600594 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.3x
300878 Zhejiang Wecome Pharmaceutical	5.7x	n/a	CN¥2.6b
603538 Ningbo Menovo Pharmaceutical	2.3x	27.8%	CN¥2.9b
002107 Shandong Wohua Pharmaceutical	3.6x	n/a	CN¥2.8b
301111 Guangdong Lifestrong Pharmacy	9.6x	n/a	CN¥3.0b
600594 Guizhou Yibai Pharmaceutical	1.3x	n/a	CN¥3.0b

Price-To-Sales vs Peers: 600594 is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (5.3x).

Price to Sales Ratio vs Industry

How does 600594's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
600664 Harbin Pharmaceutical Group	0.6x	n/a	US$1.28b
000411 Zhejiang Int'l GroupLtd	0.2x	n/a	US$758.85m
000153 Anhui Fengyuan Pharmaceutical	0.7x	n/a	US$399.69m
600781 FUREN Group PharmaceuticalLtd	0.3x	n/a	US$66.91m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 600594 is good value based on its Price-To-Sales Ratio (1.3x) compared to the CN Pharmaceuticals industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is 600594's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600594 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 600594's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

-3.0%

13.2%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

-4.2%

-23.6%